Monte Rosa Therapeutics, Inc.
GLUEMonte Rosa Therapeutics is a clinical-stage biotechnology company pioneering the development of molecular glue degraders (MGDs) to treat diseases with high unmet medical needs.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Monte Rosa Therapeutics is a clinical-stage biotechnology company pioneering the development of molecular glue degraders (MGDs) to treat diseases with high unmet medical needs. The company utilizes its proprietary QuEEN discovery engine, which integrates AI, machine learning, and structural biology, to rationally design small molecules that reprogram E3 ligases to selectively degrade therapeutically relevant proteins. Their platform focuses on targeting proteins previously considered undruggable across immunology, inflammation, cardiology, and oncology.
A leading innovator in the molecular glue degrader space with a proprietary AI-driven discovery engine and high-value strategic partnerships with global pharmaceutical leaders.
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s market cap?
- Monte Rosa Therapeutics, Inc. (GLUE) has a market capitalization of $1.9B and trades on NASDAQ.
- What is Monte Rosa Therapeutics, Inc.'s revenue and profitability?
- Monte Rosa Therapeutics, Inc. generated $43.0M in trailing twelve-month revenue with a net loss of $130.0M, representing a net margin of -302.6%, with free cash flow of -$19.7M. These figures are based on the Q1 2026 filing.
- Who are Monte Rosa Therapeutics, Inc.'s competitors?
- Monte Rosa Therapeutics, Inc.'s key competitors include Kymera Therapeutics, Inc., C4 Therapeutics, Inc., Nurix Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Monte Rosa Therapeutics, Inc. partner with?
- Monte Rosa Therapeutics, Inc.'s notable partners include Novartis, Roche.
- What subsidiaries does Monte Rosa Therapeutics, Inc. have?
- Monte Rosa Therapeutics, Inc.'s subsidiaries include Monte Rosa Therapeutics AG.
- Where is Monte Rosa Therapeutics, Inc. headquartered?
- Monte Rosa Therapeutics, Inc. is headquartered in United States of America and employs approximately 109 people. It has been publicly traded since 2021.
